Scientists find how to treat the primary cause of heart disease

Credit: Unsplash+

Recent research led by the University of Minnesota Medical School has unveiled a promising pathway to combat cardiovascular disease.

This groundbreaking study identifies a molecule called TREM2 as a unique and therapeutically relevant pathway for treating atherosclerosis, a common condition characterized by plaque buildup in arteries.

Atherosclerosis is a leading cause of cardiovascular diseases, which remain the primary cause of death and disability worldwide, according to the Centers for Disease Control and Prevention (CDC).

Understanding Atherosclerosis: Atherosclerosis is a chronic condition that develops when plaque, a waxy substance composed of cholesterol, fat, calcium, and other substances, accumulates in the inner walls of arteries.

Over time, this buildup narrows and hardens the arteries, restricting blood flow. Atherosclerosis can affect arteries throughout the body, increasing the risk of heart attacks, strokes, and other cardiovascular complications.

The Role of Inflammation: Inflammation is a key contributor to the development of atherosclerosis.

While current treatments primarily focus on lowering LDL cholesterol levels, researchers have long recognized that inflammation also plays a significant role in plaque formation within arteries.

The TREM2 Pathway: The recent study conducted by the University of Minnesota Medical School highlights the molecule TREM2 as a potential breakthrough in addressing atherosclerosis.

TREM2, which stands for Triggering Receptor Expressed on Myeloid cells 2, is a molecule found on white blood cells called macrophages, which are essential components of the immune system.

Research Findings: Using preclinical models of atherosclerosis, the research team discovered that the progression of the disease was significantly inhibited when they deleted the TREM2 gene in macrophages.

This finding suggests that TREM2 plays a crucial role in the development of atherosclerosis and offers a promising avenue for therapeutic intervention.

Moreover, the study revealed that targeted deletion of the TREM2 pathway effectively reduced pre-existing atherosclerotic disease. This indicates that TREM2 may serve as a potential immunotherapeutic target for managing cardiovascular disease risk.

Future Research and Collaboration: The research is far from over. Alector, Inc., a pharmaceutical company, has partnered with the University of Minnesota to advance this groundbreaking discovery.

Their collaboration will involve preclinical testing of TREM2-targeted antibodies with the aim of combatting the progression of atherosclerosis.

Conclusion: The identification of the TREM2 pathway as a potential target for treating atherosclerosis represents a significant step forward in the fight against cardiovascular disease.

While current treatments mainly concentrate on lowering LDL cholesterol levels, this research introduces a new avenue for preventing and managing atherosclerosis by addressing inflammation at the molecular level.

As cardiovascular diseases continue to pose a global health challenge, innovative approaches like targeting TREM2 hold promise for improving patient outcomes and reducing the burden of these life-threatening conditions.

Further research and clinical trials will be instrumental in determining the effectiveness and safety of TREM2-based therapies, potentially leading to transformative treatments for atherosclerosis and related cardiovascular diseases.

If you care about heart health, please read studies about how to control your cholesterol to prevent heart attacks and strokes, and how to reverse heart failure with diet.

For more information about heart health, please see recent studies that green tea may protect your body as a vaccine, and results showing this inexpensive drug combo can protect your heart health, prevent stroke.

The research findings can be found in Nature Cardiovascular Research.

Follow us on Twitter for more articles about this topic.

Copyright © 2023 Knowridge Science Report. All rights reserved.